Research Topics
Genomes and Genes | Aaron D SchimmerSummaryAffiliation: University of Toronto Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Induction of apoptosis in lymphoid and myeloid leukemiaAaron D Schimmer
Princess Margaret Hospital, Room 9 516, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
Curr Oncol Rep 8:430-6. 2006..This review highlights compounds that target the mitochondrial, death receptor, and convergence pathways of caspase activation that are being developed for the treatment of acute leukemia...- Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formationImtiaz A Mawji
Ontario Cancer Institute, Princess Margaret Hospital, 610 University Ave, Toronto, ON, Canada, M5G 2M9
J Natl Cancer Inst 99:811-22. 2007..We hypothesized that c-Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein (FLIP), an endogenous inhibitor of death receptor signaling, may suppress anoikis... - A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesisImtiaz A Mawji
Ontario Cancer Institute, Princess Margaret Hospital, Mt Sinai Hospital, Toronto, Ontario, Canada
Cancer Res 67:8307-15. 2007..Our results suggest that FLIP is a suppressor of anoikis and inhibiting FLIP protein synthesis may be a useful antimetastatic strategy... 
Apoptosis in leukemia: from molecular pathways to targeted therapiesAaron D Schimmer
Princess Margaret Hospital, 610 University Ave, Toronto, ON, Canada M5G 2M9
Best Pract Res Clin Haematol 21:5-11. 2008..This work demonstrates both the development of new agents based on molecular mechanisms and how these agents further our understanding of the biology of apoptosis...- Clioquinol - a novel copper-dependent and independent proteasome inhibitorA D Schimmer
The Princess Margaret Hospital, The Ontario Cancer Institute, Toronto, ON, Canada
Curr Cancer Drug Targets 11:325-31. 2011..In addition, it discusses the human pharmacology and toxicology studies and how this information would guide a phase I clinical trial of this agent for patients with malignancy... - A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignanciesAaron D Schimmer
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario, Canada
Clin Lymphoma Myeloma Leuk 12:330-6. 2012..Neuropathy and abdominal pain were dose-limiting toxicities. Minimal pharmacodynamic effects were observed, and there were no clinical responses... - Male sexual function after autologous blood or marrow transplantationA D Schimmer
Autologous Blood and Marrow Transplant Long Term Follow up Research Unit, The Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
Biol Blood Marrow Transplant 7:279-83. 2001..Decreased levels of testosterone and symptoms of sexual dysfunction correlated with a diagnosis of Hodgkin's disease and may be related to the induction and salvage therapy received prior to autoBMT... - Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II studyAaron D Schimmer
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada
Clin Lymphoma Myeloma Leuk 11:433-8. 2011..We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML who did not achieve remission with initial induction chemotherapy... - Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemiaAaron D Schimmer
Ontario Cancer Institute, Princess Margaret Hospital, 610 University Ave, M5G 2M9, Toronto, ON, Canada
Curr Treat Options Oncol 8:277-86. 2007..In addition, this review will discuss how these novel therapies are being used as chemical probes to better understand the biology of the apoptosis pathway... - Inhibitor of apoptosis proteins: translating basic knowledge into clinical practiceAaron D Schimmer
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada
Cancer Res 64:7183-90. 2004..For all of these potential clinical applications, however, the challenge remains to incorporate these findings into actual clinical practice... - Targeting XIAP for the treatment of malignancyA D Schimmer
The Ontario Cancer Institute, Toronto, Ontario, Canada
Cell Death Differ 13:179-88. 2006..This review will discuss the progress being made in developing antisense and small-molecule XIAP inhibitors... - Chemical biology--understanding biology and advancing therapyAaron D Schimmer
The Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Clin Invest Med 31:E282-9. 2008..Finally, this review discusses the opportunities to identify off-patent drugs with previously unrecognized anti-cancer activity and how the prior data on the drug would permit it to be rapidly repurposed... - Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemiaAaron D Schimmer
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario, Canada M5G 2M9
J Clin Oncol 27:4741-6. 2009..We report on a phase I/II trial of the XIAP antisense oligonucleotide AEG35156 in combination with reinduction chemotherapy... - A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignanciesAaron D Schimmer
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada
Clin Cancer Res 14:8295-301. 2008..Therefore, we conducted a phase I clinical trial of the small-molecule pan-Bcl-2 inhibitor, obatoclax mesylate, in patients with refractory leukemia and myelodysplasia to assess its safety and define its optimal dose... - The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplantAaron D Schimmer
ABMT Long term Follow up Research Unit, Princess Margaret Hospital, University of Toronto, ABMT Program, Canada
Support Care Cancer 10:247-52. 2002..In conclusion, we present an inexpensive model of care for ABMT survivors that can be extended to adult survivors of malignancy not treated by ABMT... - The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cellsSumaiya Sharmeen
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Blood 116:3593-603. 2010..Thus, given its known toxicology and pharmacology, ivermectin could be rapidly advanced into clinical trial for leukemia... - Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cellsYanina Eberhard
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Blood 114:3064-73. 2009..Thus, in summary, CPX has previously unrecognized anticancer activity at concentrations that are pharmacologically achievable. Therefore, CPX could be rapidly repurposed for the treatment of malignancies, including leukemia and myeloma... - Effect of noncompetitive proteasome inhibition on bortezomib resistanceXiaoming Li
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
J Natl Cancer Inst 102:1069-82. 2010..We hypothesized that proteasome inhibitors that act through a noncompetitive mechanism might overcome some forms of bortezomib resistance... 
Suppression of cancer progression by MGAT1 shRNA knockdownReza Beheshti Zavareh
Ontario Cancer Institute, Princess Margaret Hospital, and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
PLoS ONE 7:e43721. 2012..Our results demonstrate that blocking MGAT1 is a potential target for anti-cancer therapy...- Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formationCraig D Simpson
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
Cancer Res 69:2739-47. 2009..These results suggest a potential mechanism for the observed clinical reduction in metastasis and relapse in breast cancer patients who have undergone treatments with cardiac glycosides... - Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligandsTabitha E Wood
Princess Margaret Hospital, Ontario Cancer Institute, Ontario, Canada
Mol Cancer Ther 9:246-56. 2010..Thus, we have identified a selective HDAC inhibitor and showed that selective HDAC inhibition sensitizes cells to death ligands, thereby highlighting a new mechanism to overcome resistance to death receptor ligands... - Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancerEmma Ito
Department of Medical Biophysics, University of Toronto, Ontario, Canada
Mol Pharmacol 76:969-83. 2009..Thus, using an HTS approach, CTAB was identified as a potential apoptogenic quaternary ammonium compound possessing in vitro and in vivo efficacy against HNC models... - The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myelomaG Wei Xu
The Princess Margaret Hospital, The Ontario Cancer Institute, Toronto, ON, Canada
Blood 115:2251-9. 2010..Thus, our work highlights the E1 enzyme as a novel target for the treatment of hematologic malignancies... - Inhibition of the sodium/potassium ATPase impairs N-glycan expression and functionReza Beheshti Zavareh
Ontario Cancer Institute, Princess Margaret Hospital, Canada
Cancer Res 68:6688-97. 2008..These molecules can be used as tools to better understand the role of N-glycans in normal and malignant cells. Moreover, these results may partly explain the anticancer effect of CGs in cardiovascular patients... - Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimenElena Liew
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Leuk Res 36:1517-20. 2012..The outcome of adult ALL relapsing after treatment was therefore poor, and novel salvage strategies are needed to improve outcomes... - Novel proteasome inhibitors to overcome bortezomib resistanceAmy M Ruschak
Department of Molecular Genetics, The University of Toronto, Toronto, ON, Canada
J Natl Cancer Inst 103:1007-17. 2011..We then focus on the molecular biology, chemistry, and the preclinical and clinical efficacy of novel proteasome inhibitors as strategies to inhibit this target and overcome some forms of bortezomib resistance... - The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myelomaPaul A Spagnuolo
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON
Blood 115:4824-33. 2010..Therefore, flubendazole is a novel microtubule inhibitor that displays preclinical activity in leukemia and myeloma... - Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 proteinVijay M Shahani
Department of Chemistry, University of Toronto, Mississauga, ON, Canada
Bioorg Med Chem 19:1823-38. 2011..The effect of compounds 14aa and 14aa-OH are accompanied by a moderate loss of cell viability... - Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocolSanthosh Thyagu
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Br J Haematol 158:506-14. 2012..The combination of imatinib with a paediatric-based regimen in adults produced high response rates, but was associated with considerable toxicity and high non-relapse mortality post-HSCT... - A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell deathTabitha E Wood
Princess Margaret Hospital, Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario, Canada
Mol Cancer Ther 7:3546-55. 2008..Thus, fasentin is a novel inhibitor of glucose transport that blocks glucose uptake and highlights a new mechanism to sensitize cells to death ligands... - Inhibition of SREBP1 sensitizes cells to death ligandsYanina Eberhard
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Oncotarget 2:186-96. 2011..Thus, inhibition of SREBP1 or its downstream target fatty acid synthase sensitizes resistant cells to death ligands... - Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemiaMarko Skrtic
Campbell Family Cancer Research Institute, Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada
Cancer Cell 20:674-88. 2011.... - Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemiaLalit Saini
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Am J Hematol 87:323-6. 2012..We conclude that outpatient-based consolidation therapy can be safely undertaken in a substantial proportion of fit older patients with AML... - Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cellsSonali B Fonseca
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, ON M5S1A8, Canada
Chem Biol 18:445-53. 2011..This retention of activity is observed even in cells with resistance to chlorambucil or disabled apoptotic triggering... - Cyproheptadine displays preclinical activity in myeloma and leukemiaXinliang Mao
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Blood 112:760-9. 2008..Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer... - Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapySusan Y Kao
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
Br J Haematol 143:738-43. 2008..Nine out of 14 evaluable patients in the attenuated IST group had durable responses to treatment, suggesting that patients not suitable for standard IST can still benefit from attenuated IST... - Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimenJohn M Storring
Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Br J Haematol 146:76-85. 2009..Effective delivery of asparaginase dosing appears to be important in achieving an optimal antileukaemic effect... - Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancersSiyuan Song
Department of Biochemistry, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada
Cancer Res 71:7628-39. 2011..Taken together, our results reveal a critical requirement for iron in Wnt signaling and they show that iron chelation serves as an effective mechanism to inhibit Wnt signaling in humans... - A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell deathRose Hurren
Ontario Cancer Institute, Princess Margaret Hospital, 610 University Ave, Toronto, ON, Canada M5G 2M9
Apoptosis 13:748-55. 2008..Thus, Q(2) is a novel quinolinium with preclinical activity in malignancies such as leukemia and myeloma and warrants further investigation... - Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemiaMurtadha Al-Khabori
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Leuk Lymphoma 51:61-5. 2010..non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL... - Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemiaJonathan How
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Cancer 118:6110-7. 2012.... - A genome wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistanceCraig D Simpson
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada
Apoptosis 17:666-78. 2012..Thus, ABHD4 is a novel genetic regulator of anoikis sensitivity... - Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapyJoseph M Brandwein
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Am J Hematol 83:54-8. 2008..Patients achieving CR are at high risk of relapse and should be considered for allogeneic BMT or novel strategies to attempt to reduce relapse rates... - Anoikis resistance and tumor metastasisCraig D Simpson
Ontario Cancer Institute, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
Cancer Lett 272:177-85. 2008.... - Phosphopeptide selective coordination complexes as promising SRC homology 2 domain mimeticsJoel A Drewry
Department of Chemical and Physical Sciences, University of Toronto, 3359 Mississauga Road North, Mississauga, Ontario L5L 1C6, Canada
Inorg Chem 51:8284-91. 2012..Several receptors potently disrupted cancer cell viability in breast cancer, prostate cancer, and acute myeloid leukemia cell lines... - Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancerEmma Ito
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 2M9
Sci Transl Med 3:67ra7. 2011..Thus, our study has revealed UROD as a potent tumor-selective sensitizer for both radiation and chemotherapy, with potential relevance to many human malignancies... - Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzymeJohn Paul Bacik
Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada
J Biol Chem 285:20273-80. 2010..These studies reveal structural features that further our understanding of the UBA5 enzyme reaction mechanism and provide insight into the evolution of ubiquitin activation... - Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitorsMahadeo A Sukhai
Princess Margaret Hospital the Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
J Clin Invest 123:315-28. 2013..These results demonstrate that lysosomal disruption preferentially targets AML cells and AML progenitor cells, providing a rationale for testing lysosomal disruption as a novel therapeutic strategy for AML... - Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosisShadi Mamaghani
Division of Applied Molecular Oncology, University Health Network, Toronto, Ontario, Canada
PLoS ONE 7:e41102. 2012..These results suggest that GSK-3 inhibitors might be effectively combined with TRAIL for the treatment of pancreatic cancer... - Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)Bruno C Medeiros
Department of Medical Oncology, Peincess Margaret Hospital, University Health Network, Univeristy of Toronto, Toronto, Ontario, Canada
Leuk Lymphoma 48:65-71. 2007..We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction... - Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myelomaManujendra N Saha
Division of Molecular and Cellular Biology, Toronto General Hospital Research Institute, Toronto, Ontario, Canada
PLoS ONE 7:e30215. 2012..Our study unveils a previously undescribed mechanism of RITA-induced p53-mediated apoptosis through JNK signaling pathway and provides the rationale for combination of p53 activating drugs with JNK activators in the treatment of MM... - A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localizationG Wei Xu
Ontario Cancer Institute, Princess Margaret Hospital, 610 University Ave, M5G 2M9, Toronto, ON, Canada
Apoptosis 13:413-22. 2008..Thus, a chemical biology approach has identified a molecule that shifts the localization of p53 and enhances its nuclear activity... - Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acidDebbie M Gurfinkel
The Princess Margaret Hospital and the Ontario Cancer Institute, Rm 9-516, 610 University Ave, M5G 2M9, Toronto, ON, Canada
Apoptosis 11:1463-71. 2006..Thus, disruption of the endoplasmic reticulum and alterations in calcium homeostasis are early events in AA-induced death... - The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient miceNhu-An Pham
Department of Medical Biophysics, University of Toronto, Ontario, Canada
Mol Cancer Ther 3:1239-48. 2004..Our findings suggest that, in addition to the known effects on cancer prevention, sulforaphane may have activity in established pancreatic cancer... - SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membraneKen Ichiro Watanabe
Cell Biology Program, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Apoptosis 14:77-89. 2009..These results suggest that SBDS loss results in abnormal accumulation of Fas at the plasma membrane, where it sensitizes the cells to stimulation by Fas ligand... - TROSY-based NMR evidence for a novel class of 20S proteasome inhibitorsRemco Sprangers
Departments of Molecular Genetics, Biochemistry, and Chemistry, The University of Toronto, Toronto, Ontario M5S 1A8, Canada
Biochemistry 47:6727-34. 2008..Our data thus establish a novel class of proteasome inhibitor that functions via a mechanism distinct from binding to active sites... - Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cellsXuegong Zhu
Department of Medicine, University Health Network, The Ontario Cancer Institute, 610 University Avenue 8 327, Toronto, Ontario, Canada M5G 2M9
J Clin Endocrinol Metab 93:3610-7. 2008..Epigenetic dysregulation is implicated in pituitary neoplasia as the cause of silencing of several tumor suppressor genes. However, the upstream mediators of such events remain unknown... - Catalase activity and arsenic sensitivity in acute leukemiaEmma Coe
Ontario Cancer Institute, Princess Margaret Hospital, and Department of Medical Biophysics, University of Toronto, Toronto, Canada
Leuk Lymphoma 49:1976-81. 2008..Therefore, other strategies should be explored to enhance the cytotoxicity of As2O3 in AML... - Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactionsJoel A Drewry
Department of Chemistry, University of Toronto, Toronto, Canada
Chem Commun (Camb) 46:892-4. 2010..As a proof-of-concept, functionalized bis-dipicolylamine (BDPA) copper(ii) complexes are shown to disrupt oncogenic Stat3-Stat3 protein complexes and elicit promising anti-tumour activity... - Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancyHong Chang
Princess Margaret Hospital, Room 9 516, 610 University Avenue, Toronto, Ontario, Canada
Mol Cancer Ther 6:24-30. 2007..This review will discuss Livin as a potential therapeutic target and strategies for its inhibition, including antisense oligonucleotides, small-molecule inhibitors, and immune-mediated approaches... - A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitinXinliang Mao
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Blood 110:4047-54. 2007..Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate... - New sources of drugs for hematologic malignanciesMahadeo A Sukhai
Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
Blood 117:6747-55. 2011..Finally, the mechanisms to enhance drug repurposing through increased collaborations between academia, industry, and nonprofit charitable organizations are discussed... - The toxicology of ClioquinolXinliang Mao
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
Toxicol Lett 182:1-6. 2008..Such information will aid in the design of clinical trials of oral Clioquinol for new indications such as cancer therapy... - Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screeningDavid Katz
University of Toronto, Canada
Biotechniques 44:ix-xiv. 2008..These data indicate that the 96-well CFA can be adopted as an efficient alternative assay to the 6-well CFA in evaluating single and combination therapies in vitro, providing a possible readout that could be used on a HTS platform... - Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cellsBernard P Schimmer
Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada
Endocrinology 147:2357-67. 2006..The large number of transcripts affected by ACTH anticipates a broader range of actions than previously appreciated... - Self-concept as a "BMT patient", illness intrusiveness, and engulfment in allogeneic bone marrow transplant recipientsHeather J Beanlands
Ryerson University, Toronto, ON, Canada
J Psychosom Res 55:419-25. 2003..These effects are amplified when self-experience is dominated by disease and treatment and patients feel helpless, hopeless, and distressed (engulfment)... - Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cellsBing Z Carter
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Blood 105:4043-50. 2005..Thus, polyphenylurea-based XIAP antagonsists directly induce apoptosis of leukemia cells and AML patient samples at low micromolar concentrations through a mechanism of action distinct from conventional chemotherapeutic agents... - Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activityRodger E Tiedemann
Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
J Clin Invest 118:1750-64. 2008..These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies... - Bcl-B expression in human epithelial and nonepithelial malignanciesMaryla Krajewska
Burnham Institute for Medical Research, La Jolla, California 92037, USA
Clin Cancer Res 14:3011-21. 2008..Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported... - Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapyAaron D Schimmer
The Burnham Institute, La Jolla, California 92037, USA
Cancer Res 63:1242-8. 2003..This study supports the importance of apoptosis pathways in determining response to chemotherapy and suggests that functional defects in caspase activation are prognostic in patients with leukemia... - Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activityAaron D Schimmer
The Burnham Institute, La Jolla, CA 92037, USA
Cancer Cell 5:25-35. 2004..Active compounds also suppressed growth of established tumors in xenograft models in mice, while displaying little toxicity to normal tissues. These findings validate IAPs as targets for cancer drug discovery... - Bcl-2 and apoptosis in chronic lymphocytic leukemiaAaron D Schimmer
The Burnham Institute, Room 6308, 10901 N Torrey Pines Road, La Jolla, CA 92037, USA
Curr Treat Options Oncol 4:211-8. 2003..In addition, we anticipate that in the next decade, rationally designed therapies targeting specific molecular defects in the malignant CLL lymphocytes will be introduced into the clinic... - Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptorsAaron D Schimmer
Burnham Institute for Medical Research, La Jolla, California 92037, USA
Cancer Res 66:2367-75. 2006.... - Myelodysplastic syndromes: the complexity of stem-cell diseasesSeth J Corey
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Nat Rev Cancer 7:118-29. 2007.... - Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cellsXinliang Mao
Leuk Res 32:1480-2. 2008 - Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemiaMaria Teresa Lourenco
Leuk Lymphoma 49:339-41. 2008 - Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cellsOlga Berezovskaya
The Sidney Kimmel Cancer Center, San Diego, CA 92121, USA
Cancer Res 65:2378-86. 2005..We also provide initial preclinical data on the antimetastatic efficacy of recently discovered small-molecule antagonists of XIAP...